BioMarin Buyout Rumors Continue; Price Tag Grows


Nov 21, 2013

Buyout rumors have been circulating for years surrounding what could be the largest deal in pharma since 2010, and a recent FDA advisory committee nod adds billions to the potential buyout pricetag.

Earlier this week, an FDA advisory committee recommended that BioMarin’s Vimizim drug be approved to treat the rare metabolic disease, Morquio A syndrome. A favorable FDA ruling in early 2014 would add further incentive for Big Pharma suitors to purchase BioMarin at a premium price. According to Bloomberg, Vimizim is projected by analysts to be the company’s best-selling therapy by 2017.

The roles appear to have changed for BioMarin, as the orphan drug maker with a history of buying smaller companies with promising pipelines (Huxley Pharmaceuticals, Zystor Therapeutic, Zacharon Pharmaceuticals) now finds itself on the potential buyout block.

Big names, including Sanofi, GSK and Pfizer have all been mentioned as potential suitors.

Read the Bloomberg release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments